References
- Nabhan C, Kamat S, Karl Kish J. Acute myeloid leukemia in the elderly: what constitutes treatment value?. Leuk Lymphoma. 2019;60(5):1164–1170.
- Bhatt VR, Gundabolu K, Koll T, et al. Initial therapy for acute myeloid leukemia in older patients: principles of care. Leuk Lymphoma. 2018;59(1):29–41.
- Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia, version 3.2019, NCCN Clinical Practice Guidelines in oncology. J Natl Compr Canc Netw. 2019;17(6):721–749.
- Porter ME. What is value in health care?. N Engl J Med. 2010;363(26):2477–2481.
- Béné MC, Nebe T, Bettelheim P, et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia. 2011;25(4):567–574.
- Legrand O, Perrot JY, Baudard M, et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood. 2000;96(3):870–877.
- Hoffmann MH, Klausen TW, Boegsted M, et al. Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia. Cytometry B Clin Cytom. 2012;82:123–131.
- Li S, Garrett-Bakelman FE, Chung SS, et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat Med. 2016;22(7):792–799.
- Klco JM, Spencer DH, Miller CA, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell. 2014;25(3):379–392.
- Mason KD, Juneja SK, Szer J. The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis?. Blood Rev. 2006;20(2):71–82.